| Patent application number | Description | Published |
|---|
| 20090099801 | SYSTEM AND METHOD FOR ON-LINE MONITORING AND BILLING OF POWER CONSUMPTION - The present invention comprises systems and methods related to monitoring of energy usage on a power line. In a preferred embodiment, this system comprises (a) an electronic microprocessor-controlled digital electricity metering device coupled to the power line and comprising a non-volatile non-battery-powered data-storage device, wherein the metering device is capable of interval metering and of receiving a data request and transmitting data in response to the request over the power line; and (b) a data collector (preferably, a transponder) coupled to the metering device via the power line. The data collector is preferably capable of (i) receiving data from and transmitting data to the metering device over the power line, (ii) storing data received from the metering device over the power line, and (iii) receiving data from and transmitting data to a remotely located computer (preferably, a billing computer). | 04-16-2009 |
| 20090132096 | SYSTEM AND METHOD FOR ON-LINE MONITORING AND BILLING OF POWER CONSUMPTION - The present invention comprises systems and methods related to monitoring of energy usage on a power line. In a preferred embodiment, this system comprises (a) an electronic microprocessor-controlled digital electricity metering device coupled to the power line and comprising a non-volatile non-battery-powered data-storage device, wherein the metering device is capable of interval metering and of receiving a data request and transmitting data in response to the request over the power line; and (b) a data collector (preferably, a transponder) coupled to the metering device via the power line. The data collector is preferably capable of (i) receiving data from and transmitting data to the metering device over the power line, (ii) storing data received from the metering device over the power line, and (iii) receiving data from and transmitting data to a remotely located computer (preferably, a billing computer). | 05-21-2009 |
| Patent application number | Description | Published |
|---|
| 20090055668 | Method and Apparatus for Detecting Clock Gating Opportunities in a Pipelined Electronic Circuit Design - A pipeline electronic circuit and design methodology enables power conservation in the stages of the pipeline via a simulation that identifies clock-gating opportunities among the stages of the pipeline. In one embodiment, simulation results assist a designer in the design of the pipeline electronic circuit to achieve power conservation by incorporating clock-gating circuitry among the stages of the pipeline at clock gating opportunity locations that the simulation identifies. | 02-26-2009 |
| 20090063818 | Alignment of Cache Fetch Return Data Relative to a Thread - A method of obtaining data, comprising at least one sector, for use by at least a first thread wherein each processor cycle is allocated to at least one thread, includes the steps of: requesting data for at least a first thread; upon receipt of at least a first sector of the data, determining whether the at least first sector is aligned with the at least first thread, wherein a given sector is aligned with a given thread when a processor cycle in which the given sector will be written is allocated to the given thread; responsive to a determination that the at least first sector is aligned with the at least first thread, bypassing the at least first sector, wherein bypassing a sector comprises reading the sector while it is being written; and responsive to a determination that the at least first sector is not aligned with the at least first thread, delaying the writing of the at least first sector until the occurrence of a processor cycle allocated to the at least first thread by retaining the at least first sector in at least one alignment register, thereby permitting the at least first sector to be bypassed. | 03-05-2009 |
| 20090217068 | Structure For Detecting Clock Gating Opportunities In A Pipelined Electronic Circuit Design - A design structure for a pipeline electronic processor device may be embodied in a machine readable medium for designing, manufacturing or testing a processor integrated circuit. The design structure may embody a pipeline electronic circuit that enables power conservation in the stages of the pipeline via a simulation that identifies clock-gating opportunities among the stages of the pipeline. In one embodiment, simulation results assist a designer in the design of the pipeline electronic circuit design structure to achieve power conservation by incorporating clock-gating circuitry among the stages of the pipeline at clock gating opportunity locations that the simulation identifies. | 08-27-2009 |
| 20090249349 | Power-Efficient Thread Priority Enablement - A mechanism for controlling instruction fetch and dispatch thread priority settings in a thread switch control register for reducing the occurrence of balance flushes and dispatch flushes for increased power performance of a simultaneous multi-threading data processing system. To achieve a target power efficiency mode of a processor, the illustrative embodiments receive an instruction or command from a higher-level system control to set a current power consumption of the processor. The illustrative embodiments determine a target power efficiency mode for the processor. Once the target power mode is determined, the illustrative embodiments update thread priority settings in a thread switch control register for an executing thread to control balance flush speculation and dispatch flush speculation to achieve the target power efficiency mode. | 10-01-2009 |
| Patent application number | Description | Published |
|---|
| 20090043073 | Alpha-fetoprotein peptides and uses for imaging - The invention provides diagnostic procedures wherein the presence or absence of a cell-proliferating disorder, e.g., a breast cancer, may be determined. The imaging agents of the invention include alpha-fetoprotein hydrophilic analogs which have been determined to target cancers, e.g., breast cancer, and are also anti-cell proliferating in nature. These modulators contain amino acid structures which are arranged as a hydrophilic analog of an alpha-fetoprotein. The modulator may be a peptide; a peptidomimetic; or may be in the form of a pharmaceutically acceptable scaffold, such as a polycyclic hydrocarbon to which is attached the necessary amino acid structures. The imaging agents of the invention further comprise an imaging moiety that allows for the imaging of the area targeted by the imaging agent. | 02-12-2009 |
| 20100249040 | Alpha-fetoprotein peptides and uses thereof - Therapeutic compounds which are cell proliferation modulators, preferably inhibitors. These modulators contain amino acid structures that are arranged as a hydrophilic analog of an alpha-fetoprotein. The modulator may be a peptide itself, e.g., an octapeptide like that of SEQ ID NO: 5; a peptidomimetic; or may be in the form of a pharmaceutically acceptable scaffold, such as a polycyclic hydrocarbon to which is attached the necessary amino acid structures for biological and/or chemical activity. The modulators of the invention are distinguished in one aspect over previous compounds in that they are orally active, and therefore do not have to be injected into the patient. The compositions and methods are useful for reducing estrogen-dependent and estrogen-independent growth of cells, and treating or preventing cancer, such as breast cancer, brain cancer, head-and-neck cancer, thyroid cancer, lung cancer, colon cancer, ovarian cancer, prostate cancer, cervical cancer, and skin cancer. The treatment or prevention methods can include the use of tamoxifen therapy in combination with the peptide therapy. | 09-30-2010 |
| 20110269692 | ALPHA-FETOPROTEIN PEPTIDES AND USES THEREOF - Therapeutic compounds which are cell proliferation modulators, preferably inhibitors. These modulators contain amino acid structures that are arranged as a hydrophilic analog of an alpha-fetoprotein. The modulator may be a peptide itself, e.g., an octapeptide like that of SEQ ID NO: 5; a peptidomimetic; or may be in the form of a pharmaceutically acceptable scaffold, such as a polycyclic hydrocarbon to which is attached the necessary amino acid structures for biological and/or chemical activity. The modulators of the invention are distinguished in one aspect over previous compounds in that they are orally active, and therefore do not have to be injected into the patient. The compositions and methods are useful for reducing estrogen-dependent and estrogen-independent growth of cells, and treating or preventing cancer, such as breast cancer, brain cancer, head-and-neck cancer, thyroid cancer, lung cancer, colon cancer, ovarian cancer, prostate cancer, cervical cancer, and skin cancer. The treatment or prevention methods can include the use of tamoxifen therapy in combination with the peptide therapy. | 11-03-2011 |
| Patent application number | Description | Published |
|---|
| 20090305265 | INTERLEUKIN-33 (IL-33) FOR THE DIAGNOSIS AND PROGNOSIS OF CARDIOVASCULAR DISEASE - The present invention includes methods for the use of interleukin-33 (IL-33) in the diagnosis of cardiovascular conditions including acute coronary syndrome (ACS), myocardial infarction, and/or heart failure, angina, cardiac hypertrophy, arteriosclerosis, myocarditis, pancarditis, endocarditis, stroke and/or pulmonary embolism and the determination of the severity of such conditions (prognosis). | 12-10-2009 |
| 20100009356 | DIAGNOSIS OF CARDIOVASCULAR DISEASE - This invention relates to methods for the detection of cardiovascular disease, e.g., acute coronary syndrome, heart failure and/or pulmonary embolism, in high body mass index (BMI) individuals, e.g., with a BMI of 25-29, or 30 or above, and those with impaired renal function. | 01-14-2010 |
| 20100055683 | DIAGNOSIS OF PULMONARY AND/OR CARDIOVASCULAR DISEASE - Described are methods and kits for determining the likelihood of the presence of cardiovascular disease (CVD) or pulmonary disease (PD) in a subject using ST2/Interleukin 1 Receptor Like 1 (IL1RL1) and/or Interleukin 33 (IL-33), and a biomarker for CVD, e.g., a natriuretic peptide, e.g., brain natriuretic peptide (BNP), prohormone BNP (proBNP), N-Terminal proBNP (NT-proBNP), atrial natriuretic peptide (ANP), proANP, or NT-proANP. | 03-04-2010 |
| 20100273886 | FORMULATIONS AND METHODS FOR LYOPHILIZATION AND LYOPHILATES PROVIDED THEREBY - The present invention provides compositions, methods for lyophilizing compounds and making pharmaceutical compositions, and kits providing solutions and lyophilized formulations of compounds. The compositions, methods, and kits are particularly useful in pharmaceutical applications involving therapeutic agents that have low solubility at low pH and medium pH values. Certain embodiments provide methods for lyophilizing compounds in liquid solutions, which include the steps of: a) preparing aqueous solutions of a compound of interest in the absence of buffer; b) adjusting the pH to high values of pH in order to increase the solubility of the compound of interest; and c) freeze-drying the solution to provide a lyophilized solid composition. Aqueous solutions including buffer are also disclosed. Lyophilized formulations, including micronized and non-micronized powders, are provided. | 10-28-2010 |
| 20110034560 | LIQUID FORMULATIONS OF COMPOUNDS ACTIVE AT SULFONYLUREA RECEPTORS - The invention provides liquid formulations of compounds that act at sulfonylurea receptors that are suitable for intra-venous and intra-arterial infusion. Compounds active at a sulfonylurea receptor include glibenclamide, tolbutamide, repaglinide, nateglinide, meglitinide, midaglizole, LY397364, LY389382, glyclazide, and glimepiride. Liquid formulations may be concentrated solutions suitable for storage; may be diluted (e.g., dilution of 1:1 or 1:1.2) suitable for bolus injections, and may be further diluted (e.g., dilution of 1:10 or 1:20 or more) for intravenous and intra-arterial infusion over an extended period of time. For example, a liquid formulation may include at least about 0.05 mg/ml glibenclamide in a water-based solution including 40% polyethylene glycol 300, 10% Ethanol, 50% water, at about pH 9. The solution may include a buffer, and is suitable for storage in refrigerator or at room temperature. This solution may be diluted 1:1, or more (e.g., 1:20) without precipitation of the glibenclamide. | 02-10-2011 |
| 20110053170 | Interleukin-33 (IL-33) for the Diagnosis and Prognosis of Cardiovascular Disease - The present invention includes methods for the use of interleukin-33 (IL-33) in the diagnosis of cardiovascular conditions including acute coronary syndrome (ACS), myocardial infarction, and/or heart failure, angina, cardiac hypertrophy, arteriosclerosis, myocarditis, pericarditis, endocarditis, stroke and/or pulmonary embolism and the determination of the severity of such conditions (prognosis). | 03-03-2011 |
| 20110262941 | PREDICTING MORTALITY AND DETECTING SEVERE DISEASE - Measurement of circulating ST2 and/or IL-33 concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of severe disease. | 10-27-2011 |
